You just read:

Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis

News provided by

Takeda Pharmaceutical Company Limited

Feb 16, 2018, 11:00 ET